Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides
Public ClinicalTrials.gov record NCT03695471. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Open-Label, Single-Arm Trial Using KEYTRUDA (Pembrolizumab) as Initial Systemic Therapy in the Treatment of Advanced Mycosis Fungoides
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies how well pembrolizumab works in treating patients with stage IB-IV mycosis fungoides. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Study identification
- NCT ID
- NCT03695471
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 9 participants
Conditions and interventions
Conditions
- Mycosis Fungoides
- Sezary Syndrome
- Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 4, 2020 (Actual)
- Primary completion
- Jun 21, 2023 (Actual)
- Completion
- Oct 8, 2024 (Actual)
- Last update posted
- Aug 29, 2025
2020 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Florida | Jacksonville | Florida | 32224-9980 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03695471, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 29, 2025 · Synced Oct 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03695471 live on ClinicalTrials.gov.